920972-73-2Relevant academic research and scientific papers
Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
-
, (2010/03/02)
The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a sol
4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
-
Page/Page column 12, (2009/10/21)
The present invention relates to 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide, and pharmaceutically acceptable salts and solvates thereof. It further concerns pharmaceutical compositions comprising this compound as active ingredient as well as processes
Active substance combination for the treatment of diabetes
-
Page/Page column 163-164, (2008/12/07)
The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, used to treat diabetes, a medicament comprising said active substance combination, a pharmaceutical formulation
Substituted pyrazoline for preventing weight gain
-
Page/Page column 162, (2008/12/07)
The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.
4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
-
Page/Page column 55, (2008/06/13)
The present invention relates to 4-substituted pyrazoline compounds of formula I methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
